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Anti-enteric Neuronal Antibodies and the 
Irritable Bowel Syndrome: Are They Really the 
Accused?
TO THE EDITOR: I read with immense interest the fascinating 
article entitled “Anti-enteric neuronal antibodies and the irritable 
bowel syndrome” by Wood et al,
1 which was published in January 
2012 issue of Journal of Neurogastroenterology and Motility. 
The authors have demonstrated that almost 90% of IBS patients 
exhibited positive anti-enteric neuronal antibodies which stained 
the nucleus and cytoplasm of neurons in the enteric nervous sys-
tem (ENS). Furthermore they also performed protein microarray 
analysis detecting anti-enteric neuronal antibodies reactivity for 
autoantigens in the serum of IBS patients. The antigens recog-
nized by these antibodies included a nondescript ribonucleopro-
tein (RNP-complex), small nuclear ribonuclear polypeptide A 
and Ro-5,200 kDa. The authors concluded that IBS was prob-
ably an autoimmune disease and symptoms in some IBS patients 
might be the detrimental effect of the anti-enteric neuronal anti-
bodies to the enteric neurons.
The pathophysiology of IBS is complex and multifactorial, 
including abnormal motility, visceral hypersensitivity, abnormal 
gas production and expulsion, food intolerance or allergy, in-
flammation, intestinal dysbiosis, and stress.
2,3 Immune inter-
actions of the ENS are currently receiving substantial attention in 
gastrointestinal motility disorders including IBS. Inflammatory 
neuropathy of the ENS (enteric ganglionitis) brings about neuro-
nal dysfunction, degeneration, and even results in a complete loss 
of enteric neurons.
4 Enteric ganglionitis can be either primary or 
secondary to a wide range of diseases, such as paraneoplastic, in-
fectious, and neurological disorders.
There is a limited number of studies regarding the role of an-
tibody against the enteric neurons on gastrointestinal motility 
disorders. Törnblom et al
5 demonstrated only a small number (2 
out of 12) IBS patients with inflammatory enteric neuropathy had 
antibodies directed towards neuronal ion channels (anti-volt-
age-gated potassium channels antibodies and anti-α3-acetylcho-
line receptor antibodies). Based on the high seropositive rate of 
anti-enteric neuronal antibodies in their IBS patients, Wood et al
1 
concluded that an autoimmune degenerative neuropathy and loss 
of neurons in the ENS might play a role in a subset of IBS 
patients. There are several shortcomings of this study. First, there 
is no histopathologic evidence of enteric neuropathy to correlate 
with the serology. Second, there is no available data of protein mi-
croarray analysis in control sera. Third, the presence of anti-en-
teric neuronal antibodies might not be attributable to an auto-
immune process. It has been demonstrated in rats that herpes 
simplex viruses are stored in myenteric ganglia of the gastro-
intestinal tract.
6 Furthermore, a high percentage of control sera 
(almost 60%) in Wood’s study contained anti-enteric neuronal 
antibodies. Therefore the presence of those antibodies might have 
been caused by residues after previous viral infection. 
In conclusion, whether presence of the anti-enteric neuronal 
antibodies is directly linked to gastrointestinal symptoms in pa-
tients with IBS or it is just an epiphenomenon, warrants further 
research. 
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Corrigendum
Physicians and Patients Measure Different Dimension on Assessment for Gatroesophageal Reflux Disease- 
related Symptoms
Juan Carlos Lopez-Alvarenga, Sergio Sobrino-Cossio, Ronnie Fass and Jose A Vargas-Romero
(J Neurogastroenterol Motil 2011;17:381-386; http://dx.doi.org/10.5056/jnm.2011.17.4.381)
Title of the paper was mis-typed. The correct title is “Physicians and Patients Measure Different Dimension on Assessment for 
Gastroesophageal Reflux Disease-related Symptoms.” And title of the figure was incorrectly written. The correct title of the figure is 
“Symptoms improvement after 4 weeks of treatment with pantoprazole magnesium. (A) It shows patient evaluation with 
ReQuest
TM. (B) It shows physician evaluation with a structured interview, despite the lack of correlation both measurements im-
proved significantly with treatment. Both assessments showed significant amelioration of symptoms (P< 0.05 for all variables).”